+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Drugs Market Research Reports

Gemcitabine Hydrochloride Global Market Report 2025 - Product Thumbnail Image

Gemcitabine Hydrochloride Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Lung Cancer Therapy - Global Strategic Business Report - Product Thumbnail Image

Lung Cancer Therapy - Global Strategic Business Report

  • Report
  • August 2025
  • 368 Pages
  • Global
From
Capecitabine - Global Strategic Business Report - Product Thumbnail Image

Capecitabine - Global Strategic Business Report

  • Report
  • August 2025
  • 220 Pages
  • Global
From
Methotrexate Drugs - Global Strategic Business Report - Product Thumbnail Image

Methotrexate Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 564 Pages
  • Global
From
Gemcitabine Hydrochloride - Global Strategic Business Report - Product Thumbnail Image

Gemcitabine Hydrochloride - Global Strategic Business Report

  • Report
  • August 2025
  • 380 Pages
  • Global
From
From
Doxorubicin - Global Strategic Business Report - Product Thumbnail Image

Doxorubicin - Global Strategic Business Report

  • Report
  • August 2025
  • 288 Pages
  • Global
From
Bulk Paclitaxel - Global Strategic Business Report - Product Thumbnail Image

Bulk Paclitaxel - Global Strategic Business Report

  • Report
  • August 2025
  • 184 Pages
  • Global
From
HER2+ Non Small Cell Lung Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

HER2+ Non Small Cell Lung Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Lung Adenocarcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Lung Adenocarcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Bevacizumab - Biosimilar Insight, 2025 - Product Thumbnail Image

Bevacizumab - Biosimilar Insight, 2025

  • Report
  • April 2025
  • 80 Pages
  • Global
From
ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025 - Product Thumbnail Image

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025 - Product Thumbnail Image

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2025 - Product Thumbnail Image

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2025 - Product Thumbnail Image

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments. In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more